XR Beta-R Tablet contains Metoprolol Succinate 50mg and Ramipril 5mg, a combination medication indicated for the management of hypertension and certain cardiovascular conditions. Metoprolol Succinate is a beta-1 selective adrenergic blocker that reduces heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and decreasing myocardial oxygen demand. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, leading to vasodilation, reduced aldosterone secretion, and decreased peripheral vascular resistance. The combined action of these agents provides effective blood pressure control and reduces the risk of cardiovascular events such as myocardial infarction and stroke. XR Beta-R Tablet is typically prescribed for patients requiring dual therapy to achieve optimal blood pressure targets or those with comorbid conditions like heart failure or post-myocardial infarction management. The extended-release formulation of Metoprolol Succinate ensures sustained plasma levels, allowing once-daily dosing for improved compliance. Dosage should be individualized based on patient response and tolerability. Common adverse effects may include dizziness, fatigue, cough, and hypotension. Use with caution in patients with renal impairment, bradycardia, or a history of angioedema. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy.